Momenta Pharmaceuticals, Inc. et al v. Amphastar Pharmaceuticals, Inc. et al

  1. June 19, 2019

    Amphastar To Get $60M In Settlement With Rivals

    Amphastar Pharmaceuticals Inc. announced Wednesday it will receive nearly $60 million from two rival drug companies as part of a settlement to resolve an antitrust and patent suit.

  2. May 22, 2019

    Pharmas Want Verdict Axed To Settle IP, Antitrust Disputes

    Pharmaceutical companies Amphastar, Sandoz and Momenta told a Massachusetts federal court that they have resolved their sprawling antitrust and patent battles over generic blood thinners, as long as the court agrees to nix Amphastar's win in the patent case.

  3. February 20, 2019

    Amphastar Says Rivals' Patent Loss Is Antitrust Ammo

    Amphastar Pharmaceuticals Inc. has told a Massachusetts federal judge that a chunk of its antitrust suit alleging two rivals boxed it out of the market for generic blood thinners has already been resolved in the drugmakers' separate patent dispute, pushing the court for a partial win on those claims.

  4. February 12, 2019

    Amphastar GC In On Docs Leak In Antitrust Suit, Cos. Say

    Amphastar Pharmaceuticals Inc. tried to pin a leak of confidential documents solely on a former Akin Gump Strauss Hauer & Feld LLP attorney, but the drugmaker's general counsel and another of its in-house attorneys were also complicit in the breach, according to a sanctions bid by two rival companies Monday.

  5. February 05, 2019

    Ex-Akin Gump Atty Leaked Docs In Antitrust Suit, Co. Says

    Amphastar Pharmaceuticals Inc. acknowledged Monday that its chief executive received a defendant's confidential documents in violation of a protective order in an antitrust suit, but argued the misstep by its outside counsel from Akin Gump Strauss Hauer & Feld LLP does not warrant "far-reaching and punitive" sanctions.

  6. October 12, 2017

    Trio Of Pharma Cos. Fight Post-Trial Bids In $1B Patent Row

    Three pharmaceutical companies involved in a $1 billion patent infringement suit over a quality control test for a generic blood thinner contested each other's dueling bids for post-trial relief Wednesday — including judgment or a new trial — after a jury found the patent was infringed but the claims were nonetheless invalid.

  7. September 21, 2017

    Momenta, Amphastar Fight Jury Decision In $1B Patent Suit

    After a Massachusetts federal jury shot down Momenta Pharmaceuticals and Sandoz Inc.'s $1 billion patent infringement suit against Amphastar Pharmaceuticals, regarding a quality-control test for a generic blood thinner, each of the companies on Wednesday pushed for post-trial relief, including judgment or a new trial.

  8. July 21, 2017

    Amphastar Escapes $1B Momenta, Sandoz Infringement Suit

    A Massachusetts federal jury on Friday sided with Amphastar Pharmaceuticals in a patent battle with Momenta Pharmaceuticals and Sandoz, finding that Momenta's patent for a generic blood thinner was invalid and that Momenta could not enforce it anyway.

  9. July 20, 2017

    Amphastar Asks Jury To Nix $1B Momenta Infringement Case

    Amphastar Pharmaceuticals on Thursday told a federal jury in Boston that generic competitor Momenta's "outrageous" dishonesty in developing standards for a lucrative blood thinner should end the company's patent infringement case.

  10. July 11, 2017

    Momenta Tells Jury Amphastar Ripped Off Drug Patent

    Drugmaker Momenta Pharmaceuticals Inc. and its partner in developing the first generic of the blood thinner enoxaparin told a federal jury in Boston on Tuesday that rival Amphastar stole its breakthrough testing technology, costing the Massachusetts company nearly $1 billion.